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Development of a core outcome set for
studies involving patients undergoing
major lower limb amputation for peripheral
arterial disease: study protocol for a
systematic review and identification of a
core outcome set using a Delphi survey
Graeme K. Ambler1,2, David C. Bosanquet1, Lucy Brookes-Howell3, Emma Thomas-Jones3, Cherry-Ann Waldron3,
Adrian G. K. Edwards2 and Christopher P. Twine1,2*
Abstract
Background: The development of a standardised reporting set is important to ensure that research is directed
towards the most important outcomes and that data is comparable. To ensure validity, the set must be agreed by a
consensus of stakeholders including patients, healthcare professionals and lay representatives. There is currently no
agreed core outcome set for patients undergoing major lower limb amputation for peripheral arterial disease (PAD)
for either short- or medium-term research outcomes. By developing these sets we aim to rationalise future trial
outcomes, facilitate meta-analysis and improve the quality and applicability of amputation research.
Methods/design: We will undertake a comprehensive systematic review of studies of patients undergoing major
lower limb amputation for PAD. Data regarding all primary and secondary outcomes reported in relevant studies
will be extracted and summarised as outcome domains. We will then undertake focus groups with key stakeholders
(patients, carers, health and social care workers) to collect qualitative data to identify the main short- and medium-
term research outcomes for patients undergoing major lower limb amputation. Results of the systematic review and
focus groups will be combined to create a comprehensive list of potential key outcomes. Stakeholders (patients,
researchers and health and social care workers) will then be polled to determine which of the outcomes are
considered to be important in a general context using a three-phase Delphi process. After preliminary analysis,
results will be presented at a face-to-face meeting of key stakeholders for discussion and voting on the final set of core
outcomes. This project is being run in parallel with a feasibility trial assessing perineural catheters in patients undergoing
lower limb amputation (the PLACEMENT trial). Full ethical approval has been granted for the study (Wales REC 3 reference
number 16/WA/0353).
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Discussion: Core outcome sets will be developed for short- and medium-term outcomes of research involving patients
undergoing major lower limb amputation for PAD. This will help with the design of future trials and facilitate meta-
analyses of trial data.
Trial registration: PROSPERO: CRD42017059329. Registered on 30 March 2017.
COMET: 975. Registered on 5 April 2017.
Keywords: Amputation, Peripheral arterial disease, Vascular surgical procedures, Outcome assessment (Healthcare)
Background
The rising prevalence of diabetes combined with high
historical rates of smoking have resulted in global
levels of peripheral arterial disease (PAD) exceeding
10% in 65–69 year olds [1]. Despite advances in
techniques for revascularisation, a small but signifi-
cant proportion (1–2%) of these patients will progress
to non-reconstructable or non-salvageable PAD, and
be faced with major lower limb amputation [2]. This
has led to approximately 5000 major lower limb
amputations being performed each year in the United
Kingdom alone [3]. A recent UK-wide report
highlighted the substandard outcomes experienced by
these patients; including poor pain control, delays
getting patients to the operating room and high rates
of in-hospital mortality [2]. Outcomes in the UK
appear to be worse than in other developed countries
[2]. There is, therefore, an urgent need for research
into improving outcomes for patients undergoing
lower limb amputation.
Systematic review with meta-analysis is the optimal
strategy for pooling results from multiple studies, but it
is being increasingly realised that many studies involving
similar patient cohorts report similar, but subtly differ-
ent, outcomes [4]. This heterogeneity makes meta-
analysis difficult, and it is often impossible to generate
pooled effect estimates [5]. This can result in studies
being excluded from analysis simply because their out-
comes are not directly comparable. In response to this
issue, a growing number of ‘core outcome sets’ have
been developed [6]. Core outcome sets aim to find
consensus on which key outcomes should be reported
for all studies involving a particular group of patients,
presenting a minimum standard. If adopted, future
research will then be more directly comparable. In
addition to this, they aim to reduce research waste by
directing research towards the most important
outcomes, and reduce the under-reporting of harms by
listing the important harms which should be reported in
clinical studies.
Although there has been some work examining core
outcomes for longer-term functional issues in established
amputees [7], there is no consensus about which short-
(within 30 days) and medium-term (up to 2 years)
outcomes are important to report for patients undergoing
major lower limb amputation. These definitions of short-
term and medium-term were chosen because many
established quality metrics in surgery are concerned with
outcomes such as mortality or readmission within 30 days;
and after consulting colleagues in rehabilitation, who told
us that they would regard patients 2 years after their
amputation as ‘established’ amputees. There is currently a
significant focus on the poor short- and medium-term
outcomes of amputees in the UK [3], so it is vitally
important that core outcomes sets for both short- and
medium-term outcomes are developed soon. These
should then be reported in any study involving patients
undergoing major lower limb amputation. The lack of
core outcome sets for patients undergoing major lower
limb amputation was evident to the authors when
designing a randomised controlled feasibility trial examin-
ing the use of a perineural catheter to improve pain
following major lower limb amputation (Perineural Local
Anaesthetic Catheter aftEr Major lowEr limb amputatioN
(PLACEMENT) trial) [8]. Development of these core
outcome sets will, therefore, be undertaken in tandem
with this study (Wales Research Ethics Committee (REC)
3 reference number 16/WA/0353).
The aim of the current work is to develop core outcome
sets for short- and medium-term outcomes for research
involving patients undergoing major lower limb amputa-
tion for complications of peripheral vascular disease. The
reason for restricting attention to this subgroup of ampu-
tees and excluding those patients undergoing amputation
for other reasons, such as trauma or tumour, is that these
two subsets of patients are quite distinct. Patients
undergoing amputation for complications of peripheral
vascular disease are generally older, with significant co-
morbidities. Patients undergoing amputation for trauma
or tumour are generally younger, and often otherwise
healthy. The latter patient group often return to full inde-
pendence quickly, whereas the former have a significant
risk of not even surviving admission, and often have a
prolonged, difficult rehabilitation phase. It was, therefore,
felt that core outcomes for the two groups might be quite
different, so we focussed attention on the larger subset,
which in most countries is the subset with peripheral
vascular disease.
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Drawing upon methods used in the development of
previous core outcome sets and described in The
COMET Handbook [9], the study will take a mixed-
methods approach [10], utilising both quantitative and
qualitative aspects. It will be undertaken in four key
stages as described in the Handbook: (1) a systematic
review to identify existing published outcomes; (2) focus
groups to ensure that published outcomes adequately
capture the issues which are most important to patients
undergoing amputation as well as those who care for
them; (3) a consensus (Delphi) survey; and (4) gener-
ation of the final core outcome set using the results of
the consensus survey and a nominal group technique.
The objective of this report is to describe a protocol for
the development of a core outcome set for studies of
major lower limb amputation for peripheral vascular
disease using this process.
Methods/design
Phase I: Systematic review
The first stage of core outcome set development will
involve a systematic review of published academic litera-
ture. The objective of this phase is to create a long-list
of outcome measures which have been reported in previ-
ous studies. The review will be conducted according to
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) Statement as appropriate
[11], and has been registered in the PROSPERO registry
(ID: CRD42017059329).
Criteria for considering studies
All clinical studies reporting at least one short- (within
30 days) or medium-term (up to 2 years) outcome
involving human subjects undergoing major lower limb
amputation (i.e. amputation of the lower limb above the
ankle) as a result of PAD will be included. This includes
non-interventional studies (e.g. case series, cohort and
qualitative studies), non-randomised and randomised
interventional trials. Study reports describing the same
patient sample will be included if they report different
outcomes, but outcomes which are duplicated will only
be counted once in any quantification of the frequency
of outcome reporting. Studies reporting only patients
undergoing amputation for non-ischaemic disease, such
as trauma, tumour, chronic non-ischaemic pain or
congenital malformations, will be excluded. Systematic
reviews will be included as providing a source of
additional references which might otherwise be missed.
Non-systematic reviews, commentary, editorials and
articles which discuss general principles rather than
patient cases will be excluded. Non-English language
clinical studies will be included if there is a publicly
available translation of either the abstract or full
study, and data extraction will be limited to what is
available in English.
Outcomes
All outcomes described as either primary or secondary
outcomes from included studies will be reported. When
more than a single study reports an outcome, the num-
ber and proportion of studies reporting that outcome
will be recorded.
Search strategy
Medical Literature Analysis and Retrieval System Online
(MEDLINE) and Excerpta Medica dataBASE (EMBASE)
will be searched through Ovid using the Medical Subject
Headings (MeSH) terms given in Additional file 1:
Appendix A. Titles will be screened then abstracts of
potentially relevant articles will then be retrieved,
screened and full-text articles retrieved when necessary
to determine inclusion in the study. Reference lists of
included studies will also be screened, and a search
using the ‘Related Articles’ function in Public MEDLINE
interface (PubMed) will capture any further relevant
papers. Two individuals will independently screen
studies for inclusion. Disagreements will be resolved
through discussion and consensus. A flow chart will be
presented to describe the search process and results.
Data extraction
A standardised data collection proforma will be used.
Extracted data will include the participant details (num-
ber and demographics: age, gender and study country),
study type (for example, randomised or non-randomised
controlled trial, cohort study, case series, qualitative),
interventions (if any), stated outcomes presented in the
methods (both primary and secondary) and reported
outcomes. Outcomes will be extracted verbatim. As this
study focusses on which outcomes are reported rather
than the value of those outcomes, neither study quality
nor risk of bias is relevant so will not be assessed. Data
will be extracted from 10% of studies by two independ-
ent reviewers. Concordance between reviewers will be
maximised by discussing in detail the first 10% and
coming to a consensus decision. Following this, the next
10% will also be extracted independently and concord-
ance will then be assessed by calculating Kendall’s τ
(tau) statistic for the number of extracted outcomes.
Provided that the concordance between reviewers is high
(i.e. a 95% confidence interval for the value of τ includes
zero), the remainder of studies will be extracted by a
single reviewer. If concordance is poor, discrepancies will
be investigated and a further 10% of studies will be
double-extracted. If concordance is high at this point,
the remainder of studies will be single-extracted, other-
wise double-extraction and consensus will continue.
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Results synthesis
The principal outcome of the systematic review is a list of
outcomes, with frequencies of reporting. Following gener-
ation of this (long)-list, outcomes will be grouped by the
study authors into appropriate domains in order to draw
out common themes for consideration in qualitative focus
groups, discussed below. For example ‘30-day mortality’,
‘in-hospital mortality’ and ’12-month mortality’ would all
be grouped into the domain ‘mortality’.
Phase II: Qualitative focus groups
Following the systematic review, we will conduct
focus groups with key stakeholders to identify further
outcomes not identified in the systematic review. The
stakeholders will include patients who have had a
major lower limb amputation, family/carers, surgeons,
anaesthetists, rehabilitation physicians, nurses, physio-
therapists, occupational therapists, prosthetics techni-
cians, social workers and other allied groups affiliated
to amputees and their care. If a certain group cannot
be represented in a focus group we may interview
them on a separate occasion. We anticipate three
focus groups, comprising one with patients and
carers, one with physicians and one with other
healthcare professionals, each with 6–10 participants.
This is based on guidance on focus groups in terms
of numbers of groups and numbers of participants
[12]. While the sample population is relatively small,
efforts will be made to include representatives from a
range of professions, and patients (in terms of type of
amputation, gender). The research team will be
pragmatic in their sample size and the need to
conduct further focus groups will be based on prelim-
inary analysis/facilitator field notes indicating whether
the data collected sufficiently answers the research
question [13]. In line with recent methodological
debates on the notion of saturation in qualitative
research [13], we will maintain transparency in our
approach by keeping detailed notes on our sampling
strategy. In real terms, decision on whether to sample
more participants will be based on discussions within
the research team (GA and LBH) about whether there
is sufficient breadth and depth of data, whether the
specific participants represent the research topic, and
practical aspects of recruitment (taking into consideration
attempts to invite participants, numbers declined, and
withdrawn). Informed consent will be obtained for all
participants by trained study personnel.
Data collection
We will use a flexible, semi-structured topic guide and
begin with an open discussion of issues relating to the
care of patients undergoing major lower limb amputa-
tion, the level of importance participants place on these
issues, and how these issues may change over time (i.e.
over the short- and medium-term time periods). The
first part of the interview will be guided by participants
themselves, and reference to the areas identified in the
systematic review will not be revealed. However, after
this open discussion, prompts from the outcome do-
mains developed in the systematic review may be used if
areas have not naturally occurred. The facilitator will use
these prompts to explore whether the outcome domains
revealed by the systematic review are relevant to the
real-life experiences and attitudes of the focus group
participants and whether they are comprehensive to the
concerns and needs of patients with lower limb amputa-
tions. We will encourage participants to initiate and
elaborate on topics most important to them. Participants
will be encouraged to respond directly to other partici-
pants’ responses in order to generate a group discussion.
Focus groups are likely to take around 60-90 min and
will be audio-recorded and transcribed verbatim, with
references to identifiable personal details removed. Brief
demographic details of participants will be taken by the
facilitator. Field notes will be made by the facilitator fol-
lowing the focus groups which will include reflections
on the process, overall observations, and relevant con-
textual details. The data will be managed using qualita-
tive coding software (NVivo qualitative analysis software;
QSR International Pty Ltd., Version 11). Data will be
coded, stored and analysed at the Centre for Trials
Research, and kept on encrypted storage devices. The
study is coordinated by the CTR, who will monitor and
audit study procedures. Monitoring will be conducted
independently by a qualified member of CTR staff not
participating in the day-to-day study activities.
Analysis
We will carry out thematic analysis of the focus group
transcripts, and the facilitator’s field notes [14]. Follow-
ing familiarisation with the data, LBH will develop a way
of categorising the data into themes and subthemes (the
analytical framework). We will take an inductive
approach, where the themes are identified directly from
the focus group data, without referring to the categories
identified in the systematic review. LBH and GA will dis-
cuss the framework and agree a framework between
them. LBH will then systematically code the focus group
data, using qualitative data analysis software NVivo (QSR
International Pty Ltd.), according to these themes (data
topics that are common in the dataset), but also looking
for contradictory views (negative cases). GA will code a
proportion of the dataset independently (10–20%) and
LBH and GA will meet to discuss discrepancies in coding
until consensus is reached. Any refinements will be made
to the analytical framework and reapplied to the data.
LBH will then interpret the coded data, taking into
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consideration the stakeholder group (i.e. themes
according to patient, carer, health professional type). The
next, and final stage of analysis will then involve consider-
ing this interpretation of the focus group data against the
outcome domains identified in the systematic review. GA
and LBH will identify: (1) areas where themes in the focus
group data are similar or correspond to those identified in
the systematic review; (2) areas where new themes were
initiated by focus group participants but were not found
in the systematic review; and (3) areas where themes were
found in the systematic review but not present in the
focus group data. By bringing these elements together
we will produce a list of outcome domains to be
taken forward to the consensus study.
As we will use an inductive approach in which the
data takes centre stage, the theoretical framework is not
predetermined but description will be derived from the
data itself. We will take a phenomenological approach to
attempt to uncover the meaning of the ‘lived experience’
of groups of individuals – in this case people who have
undergone major lower limb amputation and their
family, and a range of health professionals involved in
the management of patients who have undergone
amputation – on the phenomenon (issues or outcomes
of importance to patients after undergoing major lower
limb amputation). As Tavallaei and Abu (2010: p. 575)
[15] describe the major aim of phenomenology is to ‘re-
duce’ the experience individuals have about a certain
phenomenon so that finally the description of the uni-
versal essence is created which means “to grasp the very
nature of the thing” (VanManen, 1990:177) [16].
Phase III: Consensus survey
Following synthesis of results from the systematic review
and qualitative focus groups, stakeholders (patients and
health and social care workers) will be surveyed to deter-
mine which outcomes should comprise the core out-
come set for studies of lower limb amputation for PAD.
The list of stakeholders will include those participating
in the focus groups in addition to health and social care
workers, who will be invited to contribute via national
and international societies, and the corresponding
authors of studies included in phase I. This will be a
Delphi consensus process [17], and will mainly use an
online survey tool, but a paper version will also be
available for participants who prefer this. Stakeholders
will be asked to rate the putative outcomes on a 1–9
Likert-like scale, with 7–9 labelled as ‘essential’ (must be
reported in all trials), 4–6 as ‘desirable’ and 1–3 as ‘not
important’. Outcomes not achieving a mean score of
greater than 6 by the respondents will be eliminated, and
the process will proceed to a second round of voting.
In the second round, stakeholders will again be asked to
rate the putative outcomes as essential (7–9), desirable
(4–6) or not important (1–3). They will also be given the
opportunity to propose outcomes that they feel to be
essential but have been excluded from the first round.
Any additional outcomes proposed in this way will be
considered by the study authors, and added to the list of
potential core outcomes for voting. Outcomes not achiev-
ing a mean score of at least 7 will be eliminated, and the
process will proceed to a third round of voting.
In the third round, stakeholders will be asked to rate
the putative outcome measures as essential (7–9),
desirable (4–6) or not important (1–3). Outcomes not
voted ‘essential’ (7–9) by 75% of the respondents will
be eliminated.
At each stage, participants will be asked to rate
outcomes separately for short-term and medium-term
studies. This is because it is recognised that some
outcomes may be considered more or less important
depending upon the timing of the study. For example,
stakeholders may consider the rate of post-operative
pneumonia very important for short-term studies but
less important for medium-term studies, whereas the
rate of prosthetic limb prescription may be considered
very important for medium-term studies but less
important for short-term studies.
Phase IV: Synthesis of results and nominal group analysis
The ultimate goal of this research is to define core sets of
short- and medium-term outcomes for reporting by re-
search studies on patients undergoing major lower limb
amputation for PAD. The results of the consensus survey
will, therefore, be discussed at a face-to-face meeting of
key stakeholders and a nominal group technique applied
to determine a list of short-term outcomes and a second
list of medium-term outcomes which will represent the
core outcome sets. Stakeholders will include members of
the PLACEMENT Trial Management Group, along with
individuals from professions or specialties not represented
by the Group, who participated in the focus groups in
phase II. A nominal group technique will be used rather
than a straightforward vote to either accept or reject the
results of the consensus survey because of the risk that by
choosing somewhat arbitrary levels at which to eliminate
outcomes during the Delphi process, it is possible to arrive
at either a core outcome set with an enormous number of
items, or a core outcome set with only a very small num-
ber of items. By using a nominal group technique, the
members of the face-to-face meeting, therefore, have the
opportunity to present potential solutions to these prob-
lems if they arise, rather than simply voting to reject the
result of the Delphi.
Publication and dissemination of results
All publications and presentations relating to the study will
be authorised by the PLACEMENT Trial Management
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Group and will be in accordance with the main trial’s publi-
cation policy. In addition to the required final report and
monograph for the funding body, we will publish the main
study results in international, peer-reviewed, open-access
journals and present them at national and international
scientific meetings. With the assistance of our collaborators
and lay representatives we will disseminate the trial findings
to a wide audience and vigorously promote uptake of the
trial results into clinical care. This will include presentations
at meetings and written executive summaries for key
stakeholder groups such as Secondary Care Trusts, Royal
Colleges, Medical Schools and relevant patient groups.
Access to the full protocol, anonymised participant-level
data, and statistical code will be available from the
study team upon request after the main study results
have been published.
Discussion
Short- and medium-term outcomes after major lower
limb amputation are surprisingly poor, especially in the
UK [2]. Given that the global diabetes epidemic has
caused rates of PAD to rise by over a third in the first
decade of the 21st century [1], it is likely that major
lower limb amputation rates will also rise. There is,
therefore, an urgent need for high-quality research to
improve these outcomes. Core outcome sets for both
short- and medium-term outcomes are critical so that
trials can concentrate on the most important issues to
patients and healthcare workers in a way that facilitates
future meta-analysis and guideline development.
Study status
The systematic review is currently underway.
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